Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma

Weller, Michael; Felsberg, Jörg; Hentschel, Bettina; Gramatzki, Dorothee; Kubon, Nadezhda; Wolter, Marietta; Reusche, Matthias; Roth, Patrick; Krex, Dietmar; Herrlinger, Ulrich; Westphal, Manfred; Tonn, Joerg C; Regli, Luca; Maurage, Claude-Alain; von Deimling, Andreas; Pietsch, Torsten; Le Rhun, Emilie; Reifenberger, Guido

doi:10.1007/s00401-023-02662-1

Citations

Citation copied

Weller, M., Felsberg, J., Hentschel, B., Gramatzki, D., Kubon, N., Wolter, M., Reusche, M., Roth, P., Krex, D., Herrlinger, U., Westphal, M., Tonn, J. C., Regli, L., Maurage, C.-A., von Deimling, A., Pietsch, T., Le Rhun, E., & Reifenberger, G. (2024). Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma. Acta Neuropathologica, 147(1), 11. https://doi.org/10.1007/s00401-023-02662-1

Abstract

Prognostic factors and standards of care for astrocytoma, isocitrate dehydrogenase (IDH)-mutant, CNS WHO grade 4, remain poorly defined. Here we sought to explore disease characteristics, prognostic markers, and outcome in patients with this newly defined tumor type. We determined molecular biomarkers and assembled clinical and outcome data in patients with IDH-mutant astrocytomas confirmed by central pathology review. Patients were identified in the German Glioma Network cohort study; additional cohorts of patients with CNS WHO grade